Michael Frazis, Misha Saul and guests discuss the life sciences, technology, and their latest investment ideas.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
#71: Double or Nothing - Misha's new fund, the crash (and recovery), driverless cars, and UK turmoil
36:21
36:21
Play later
Play later
Lists
Like
Liked
36:21
#71: Double or Nothing - Misha's new fund, the crash (and recovery), driverless cars, and UK turmoil
…
continue reading
![Artwork](/static/images/128pixel.png)
1
#70: Clarity Pharmaceuticals, with Chairman Dr Alan Taylor
1:19:02
1:19:02
Play later
Play later
Lists
Like
Liked
1:19:02
Dr Alan Taylor discusses Clarity Pharmaceuticals in depth.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
#69: Droneshield: Defending against the modern horrors of war, with CEO Oleg Vornik
1:01:46
1:01:46
Play later
Play later
Lists
Like
Liked
1:01:46
It must be a uniquely modern horror to see a drone flying towards you with a grenade strapped, and it must be all the worse to know your last moments are being filmed. Drones are now ubiquitous across the battlefields of Ukraine, Gaza, and shipping lanes in the Middle East. Costing relative pittances, cheap drones loaded with explosives can destroy…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Frazpod #68: Dodging the bloodbath in midcap tech
20:52
20:52
Play later
Play later
Lists
Like
Liked
20:52
Dodging the bloodbath in midcap tech
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Frazpod #67 - Clarity Pharma, Curvebeam AI, Transmedics and AMD
19:33
19:33
Play later
Play later
Lists
Like
Liked
19:33
Clarity Pharmaceuticals Success: Clarity Pharmaceuticals reported a significant response in a patient with metastatic castrate-resistant prostate cancer. The patient received two cycles of copper 67 Biss. PSMA, and after six months from the second dose, there was no evidence of PSA, indicating a potential cure. This is noteworthy because the patien…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode #66: A crack in the semi facade? Angus Walker joins us
34:45
34:45
Play later
Play later
Lists
Like
Liked
34:45
Episode #66: A crack in the semi facade? Angus Walker joins us
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode #65 - Interesting perspectives from Microsoft
23:19
23:19
Play later
Play later
Lists
Like
Liked
23:19
Interesting perspectives from Microsoft
…
continue reading
Semis, Tesla and interest rates, what we're looking at right now
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Frazis Capital Podcast #63: The three revolutions of 2023 and where they will go in 2024.
22:18
22:18
Play later
Play later
Lists
Like
Liked
22:18
The three revolutions of 2023 and where they will go in 2024. And our top ASX pick...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Frazis Capital Podcast #62: Medtech, liquidity, and talking computers
14:40
14:40
Play later
Play later
Lists
Like
Liked
14:40
Medtech, liquidity, and talking computers
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Frazis Capital Podcast #61: Bond yields hit cycle highs, medtech takes a GLP-pounding, Nvidia and Microsoft do some cool science, and all roads in semiconductors lead to TSMC.
37:23
37:23
Play later
Play later
Lists
Like
Liked
37:23
Bond yields hit cycle highs, medtech takes a GLP-pounding, Nvidia and Microsoft do some cool science, and all roads in semiconductors lead to TSMC.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #16: Qantas scandal, an aggressive move in capital markets, a new IPO, and dodgy Government energy data
20:31
20:31
Play later
Play later
Lists
Like
Liked
20:31
Double or Nothing #16: Qantas scandal, an aggressive move in capital markets, a new IPO, and dodgy Government energy data.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #15 - Ozempic, AI in the sex industry, drug discovery, Stefan Zweig
32:45
32:45
Play later
Play later
Lists
Like
Liked
32:45
Ozempic, AI in the sex industry, drug discovery, Stefan Zweig
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #14: Michael Frazis and Misha Saul talk markets
20:55
20:55
Play later
Play later
Lists
Like
Liked
20:55
Double or Nothing #14: Michael Frazis and Misha Saul talk markets
…
continue reading
![Artwork](/static/images/128pixel.png)
1
State of the Market: the winners and losers in big tech cost outs
27:57
27:57
Play later
Play later
Lists
Like
Liked
27:57
State of the Market: the winners and losers in big tech cost outs
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #13: Submarines and Silicon Valley Bank
29:44
29:44
Play later
Play later
Lists
Like
Liked
29:44
Michael Frazis and Misha Saul talk Silicon Valley bank and Submarines
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing Episode #12: ChatGPT, Cortes and the Aztecs
38:44
38:44
Play later
Play later
Lists
Like
Liked
38:44
Double or Nothing Episode #12: ChatGPT, Cortes and the Aztecs.
…
continue reading
Michael Frazis gives an update on markets and technology.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #11: Chess, inflation, AI, software, stocks
39:18
39:18
Play later
Play later
Lists
Like
Liked
39:18
Misha Saul and Michael Frazis talk markets
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #10: Crowdstrike, inflation, 2023
53:09
53:09
Play later
Play later
Lists
Like
Liked
53:09
Double or Nothing #10: Crowdstrike, inflation, 2023
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #9: Grindr IPO, Sunrise, and inflation rolls over
41:44
41:44
Play later
Play later
Lists
Like
Liked
41:44
0:12 – Latest (deflationary) inflation data 6:42 – Investing strategies 10:30 – Tesla’s journey and the switch to self-driving capabilities 12:56 – David Walsh’s presentation at Sohn Conference on professional gambling 14:46 – Grindr IPO 21:36 – Recap of Blackbird’s Sunrise startup conference and thoughts on private markets 31:44 – Lessons learned …
…
continue reading
Michael Frazis and Misha Saul talk SBF and inflation.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #7: Nuclear war? And Facebook, Square, Microsoft, Google
57:20
57:20
Play later
Play later
Lists
Like
Liked
57:20
Double or Nothing #7: Nuclear war? And Facebook, Square, Microsoft, Google
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #6: Run on the pound? And private equity does deals
45:44
45:44
Play later
Play later
Lists
Like
Liked
45:44
Misha Saul and Michael Frazis discuss latest developments in global markets.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #5: Adobe buys Figma, Ancient and Modern heroes, and CPI prints
44:24
44:24
Play later
Play later
Lists
Like
Liked
44:24
Double or Nothing with Michael Frazis and Misha Saul. Adobe buys Figma, Ancient and Modern heroes, and CPI prints
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #4: Kim Kardashian's private equity play, the collapse in US gas prices, Twilio, Whitehaven and VC
32:31
32:31
Play later
Play later
Lists
Like
Liked
32:31
0:32 – Passing of Queen Elizabeth II 7:35 – Kim Kardashian’s new private equity play 9:16 – Collapse in price of crude oil 13:12 – Market and inflation outlook 15:32 – Twilio 21:19 – Whitehaven Coal 24:37 – Update on VC Fund deals 32:02 – Summary and wrap-up
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #3: Artificial intelligence gets creative and Powell speaks at Jackson Hole
47:24
47:24
Play later
Play later
Lists
Like
Liked
47:24
Artificial intelligence gets creative and Powell speaks at Jackson Hole
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Double or Nothing #2: Qantas, NVDA, Farfetch, Nathan Tinkler and Fortescue
49:50
49:50
Play later
Play later
Lists
Like
Liked
49:50
Double or Nothing with Misha Saul and Michael Frazis 0:15 – Preview and thoughts on Jerome Powell’s upcoming speech 1:00 – Update on Nvidia’s recent earnings and the wider semiconductor industry 12:10 – Farfetch update and latest earnings 15:45 – Notable small cap and GARP stocks 17:23 – Qantas recent performance and share buyback announcement 22:4…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New Format with Misha Saul. Double or Nothing Episode #1
1:01:16
1:01:16
Play later
Play later
Lists
Like
Liked
1:01:16
Trialling a new format, and joined by Misha Saul. Please let us know what you think!
…
continue reading
Michael Frazis gives a market update. Detailed notes to follow.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode #59: A cure for Dystonia with Dr Stephen Tisch
45:48
45:48
Play later
Play later
Lists
Like
Liked
45:48
An interview with Dr Stephen Tisch, who is researching treatment methods for dystonia at St Vincent's Hospital, Sydney. If you would like to support Neurology and Neurosciences Research at St Vincent’s please visit www.supportstvincents.com click Donate, and select 'Neurosciences Research' from the drop-down menu. Or contact Nicole at the St Vincen…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode #58: Equity rotation and the tech sell-off
33:46
33:46
Play later
Play later
Lists
Like
Liked
33:46
Strategy update recorded live on 22 December 2021 (Timestamps to follow)
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode #57: Misha Saul on markets, life, family, and violence in Western society
1:35:54
1:35:54
Play later
Play later
Lists
Like
Liked
1:35:54
Misha Saul on markets, life, family, and violence in Western society
…
continue reading
Michael Frazis reviews the market. 1:35 – Fallen angels & Fed balance sheet taper 3:53 – Comments on Coupa 7:26 – Lightspeed 8:35 – Teladoc 13:15 – Twilio 14:40 – Roku 18:10 – Upstart 19:16 – EBR Systems 20:40 – PayPal and Visa 24:52 – Coupang 29:50 – Thoughts on inflation 31:46 – Question #1: Sea Limited 32:12 – Question #2: Comments on mid-cap gr…
…
continue reading
1:00 – Thoughts on the recent inflation data from the US3:06 – The 6% differential between the Fed funds rate and inflation, and its impact on the economy4:31 – Parallels with inflation spikes in the seventies and nineties7:36 – The effect of inflation on the Australian dollar7:46 – The effect of inflation on companies – Cloudflare9:00 – Comments o…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 54: New venture fund, Web3, Zillow vs Opendoor, and questions answered
52:40
52:40
Play later
Play later
Lists
Like
Liked
52:40
0:58 Launch of our Venture Fund 3:04 The benefits of pre-IPO access and our investment in Camplify 4:58 Private access to fast growing companies like Mawson Infrastructure 6:05 Zillow’s shrinking growth model 11:05 Comparative management decisions between Opendoor and Zillow 15:54 More on Zillow’s travails and management 17:29 The importance of cus…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 53: How to build a deep tech company in aerospace from scratch, with Henry Bilinsky, founderCEO of MicroTau
51:08
51:08
Play later
Play later
Lists
Like
Liked
51:08
Henry joins us to talk about his journey and experiences with surface science, engineering, and the US Airforce. Timestamps 0:35 – How did MicroTau come to be? 2:08 – Henry discusses his involvement with InnoCentive challenges 5:16 – A challenge from the US Air Force Research Laboratory 6:26 – What is drag? 8:26 – How riblets found on shark skin ca…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 52: 20 September 2021 Update and Questions Answered
41:11
41:11
Play later
Play later
Lists
Like
Liked
41:11
Michael Frazis gives an update and answers questions. 0:26 – Introduction 1:10 – Performance update 1:58 – Comments on the NASDAQ100’s strong rally 2:46 – The performance of small-mid cap companies 3:38 – An analyse of where our returns have come from over the years 4:20 – Our past investment in bluebird bio 5:39 – Our IPO/pre-IPO investments in th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 51: New antibodies, vaccines, and our portfolio companies Cettire, Futu, and Camplify report
24:22
24:22
Play later
Play later
Lists
Like
Liked
24:22
Timestamps 0:15 Introduction to our strategy 2:55 How a company can lose money and still create value 4:38 Avoiding ‘deep value’ traps 5:30 Update on 2021 fund performance 6:50 How we’re investing in China 9:00 Update on FUTU’s Q2 results and why we bought more 12:18 Recently approved antibodies for COVID-19 – cause for optimism? 16:23 Update on Ce…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 50: Reporting season and the next big thing in the life sciences
49:15
49:15
Play later
Play later
Lists
Like
Liked
49:15
Michael Frazis gives an update
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 49: Regulatory crackdown in China and Square's acquisition of Afterpay
28:24
28:24
Play later
Play later
Lists
Like
Liked
28:24
Michael Frazis gives an update.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 48: SALT interview with Rachel Pether - true love and explosive growth
39:38
39:38
Play later
Play later
Lists
Like
Liked
39:38
Michael Frazis describes his investment company’s strategy that involves a 30-40 year view, not panicking and diverting the approach during dips and rallies. Evaluating growth stocks involves identifying customer love for a product or service which acts a key indicator of explosive growth potential. This approach is utilized in picking winners in i…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 47: A disastrous decision from the FDA
13:24
13:24
Play later
Play later
Lists
Like
Liked
13:24
Michael Frazis attempts to understand the FDA's decision to approve Biogen's aducanumab for Alzheimer's and the possible ramifications.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 46: Strategy in the Life Sciences
31:22
31:22
Play later
Play later
Lists
Like
Liked
31:22
Timestamps · 0:32 – Our fast-growing portfolio companies· 2:21 - Frazis life sciences strategy update· 5:18 – RNAi Biology· 7:15 – Alnylam: RNAi clinical development pipeline and recent execution· 8:16 – Timing and valuation in life sciences· 9:26 – What do we think of CRISPER?· 11:03 – Companies targeting sickle cell disease· 11:56 – Companies tar…
…
continue reading
Michael Frazis discusses the growth sell-off in equities as of 15 May 2021.
…
continue reading
Dr. Robert Stretch is a specialist in Pulmonary, Critical Care & Sleep Medicine. After graduating from Yale School of Medicine in 2014, he completed subspecialty training at BIDMC, a Harvard teaching hospital in Boston, and UCLA Medical Center in Los Angeles. Timestamps 0:05 – Introducing Robert Stretch 0:25 – Robert’s journey studying medicine in …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 43: Strategy update 22 April 2021
37:41
37:41
Play later
Play later
Lists
Like
Liked
37:41
0:15 – Introduction to Frazis Capital Partners. 1:45 – Sell-off trends and SPAC’s. 3:57 – Growth stocks outperforming tech indices. 6:45 – Standpoint on growth stocks. 9:18 – Software’s strong run. 11:05 – Multiple contractions and what this means. 13:30 – Teladoc Health. 14:20 – View on Appharvest. 16:45 – Batteries & developments in the lithium s…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 42: Brian Hartzer, CEO of Westpac from 2014-2020, on leadership, culture and financial technology
59:38
59:38
Play later
Play later
Lists
Like
Liked
59:38
Brian Hartzer joins us to talk about his new book 'The Leadership Star', available from Amazon. Brian was CEO of Westpac from 2014-2020. For those who don't know Westpac is Australia's second largest bank with over $800 billion of assets. Brian discusses his 'Leadership Star' framework and pivotal moments in Australia's banking history. Brian also …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 41: Where to next? SPACs, rising interest rates and tech stocks
28:50
28:50
Play later
Play later
Lists
Like
Liked
28:50
Michael Frazis gives an update on SPACs, rising interest rates, tech valuations and what might happen next. Timestamps 1:35 - Quick review of 2021 2:30 - Thoughts on Cathie Wood and ARK 3:59 - Expansions and contractions in software multiples 7:40 - Snowflake 8:47 - SPACs: why we like them and why they're dangerous (hint: the same reason) 12:02 - W…
…
continue reading
January 2021 - one of the more amusing weeks of finance. 0:57 - The short squeeze 2:31 - The reality of Robinhood's 'free' trades 5:08 - The hidden consequences of Hedge Fund strategy 6:51 - How useful is management access? 9:56 - The gamma squeeze 12:15 - How this forced people to rethink how they discuss finance? 13:39 - Is the squeeze squoze? 14…
…
continue reading